---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009599"
form_type: "8-K"
ticker: "IMNN"
cik: "0000749647"
company_name: "Imunon, Inc."
filed_at: "2023-03-30T23:59:59+00:00"
generated_at: "2026-06-17T09:52:23.959155+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Imunon reports 2022 net loss of $35.9M ($5.03/share); cash $38.9M funds into 2025

## Summary
- Net loss $35.9M vs $20.8M in 2021; operating expenses up 18% to $25.4M.
- Non-cash impairment charge of $13.4M on IPR&D asset; $4.5M interest from preferred stock redemption.
- Cash $38.9M at year-end; expects to fund operations into 2025.
- OVATION 2 study fully enrolled; Phase 1/2 with bevacizumab opened.
- PLACCINE NHP data shows comparable protection to mRNA; stability >9 months at 4°C.

## SEC filing metadata
- accession: 0001493152-23-009599
- form_type: 8-K
- ticker: IMNN
- cik: 0000749647
- company_name: Imunon, Inc.
- filed_at: 2023-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009599
- JSON: https://secwatch.observer/filing/0001493152-23-009599.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009599.txt

## Key facts
- Earnings Releases
  Imunon, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 30, 2023, Imunon, Inc. issued a press release reporting its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/749647/000149315223009599/0001493152-23-009599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.